The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...

No cases of potassium levels exceeding 6.0 mmol/L were observed.